Market Signal Briefing

A F-16V lands at the air base in Hualien, Taiwan, August 17, 2022. REUTERS/Ann Wang Purchase Licensing Rights, opens new tab

SummaryCompaniesTaiwan faces delays in US weapons deliveriesLockheed Martin: committed to Taiwan's security goalsUS in 2019 approved $8 bln sale of F-16 fighter jets to TaiwanTAIPEI, March 22 (Reuters) - Deliveries of delayed F-16V fighter jets for Taiwan will begin this ‌year with production at "full capacity", the island's defence ministry said after senior defence officials visited the United States.

Taiwan, which faces a rising military threat from China, has complained of repeated delays ​to weapons ordered from the U.S., the most important international backer and ​arms supplier for the island, which Beijing claims as its ⁠territory.

The Reuters Iran Briefing newsletter keeps you informed with the latest developments and analysis of the Iran war. Sign up here.

The United States in 2019 approved an $8 billion sale of Lockheed Martin (LMT.N), opens new tab F-16 ​fighter jets to Taiwan, a deal that would take the island's F-16 fleet ​to more than 200 jets, but the project has been hit by issues including software problems.

Deputy Minister Hsu Szu-chien, accompanied by Air Force Deputy Chief of Staff Tien Chung-yi, visited Lockheed ​Martin's F-16V assembly line in South Carolina on Monday to view the ​first aircraft, Taiwan's defence ministry said in a statement late on Saturday.

Deliveries will begin this year, ‌the ⁠ministry said, without elaborating.

Lockheed Martin has assigned several hundred personnel to assemble the remaining aircraft, and "there are no bottlenecks in either parts supply or manpower; production is proceeding at full capacity on a two-shift schedule", it said.

Lockheed Martin said ​in a statement that ​it was committed ⁠to "delivering advanced deterrence capabilities to support Taiwan's security goals".

"We continue to work closely with the U.S. government to accelerate ​delivery where possible," it said.

Because the F-16V is a new ​model specially ⁠designed for Taiwan, continued test flights are still needed to fine-tune its systems, and tests must be carefully carried out, the ministry said.

Taiwan has converted 141 older ⁠F-16A/B jets ​into the F-16V type and has ordered 66 ​new F-16Vs, which have advanced avionics, weapons and radar systems to better face down the Chinese ​air force, including its stealthy J-20 fighters.

Reporting by Ben Blanchard; Editing by William Mallard

Our Standards: The Thomson Reuters Trust Principles., opens new tab

New York, New York--(Newsfile Corp. - March 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Soleno Phase 3 clinical trial program for diazoxide choline extended-release tablets ("DCCR") had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with Prader-Willi syndrome ("PWS") posed materially greater safety risks than disclosed by Soleno or its executives; and (3) as a result, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289475

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - March 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased PomDoctor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the PomDoctor class action, go to https://rosenlegal.com/submit-form/?case_id=52621 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) PomDoctor was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) PomDoctor's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants' positive statements about PomDoctor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the PomDoctor class action, go to https://rosenlegal.com/submit-form/?case_id=52621 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289464

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - March 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lakeland Industries, Inc. (NASDAQ: LAKE) between December 1, 2023 and December 9, 2025, inclusive (the "Class Period"), of the important April 24, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Lakeland securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lakeland class action, go to https://rosenlegal.com/submit-form/?case_id=50020 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 24, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Lakeland was experiencing significant, sustained issues with its Pacific Helmets and Jolly businesses, including, inter alia, shipping-related delays, production issues, and slower than expected rollout of new products; (2) accordingly, defendants overstated the anticipated and actual positive impact of these businesses on Lakeland's financial results, as well as the overall strength and quality of Pacific Helmets' and Jolly's respective operations; (3) Lakeland's business and financial results were significantly deteriorating because of, inter alia, tariff-related headwinds and timing, certification delays, and material flow issues in its acquired businesses; (4) accordingly, defendants overstated the strength of their tariff mitigation measures and "small, strategic, and quick" ("SSQ") M&A strategy; (5) as a result of all the foregoing issues, defendants' financial guidance was unreliable; and (6) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lakeland class action, go to https://rosenlegal.com/submit-form/?case_id=50020 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289466

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Corey Baker, Chief Financial Officer of The Vita Coco Company, Inc. (COCO 2.04%), disclosed the sale of 4,000 shares of common stock on March 17, 2026 and March 18, 2026, as detailed in the SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)4,000Transaction value~$236,000Post-transaction shares (direct)27,951Post-transaction value (direct ownership)~$1.56 millionTransaction value based on SEC Form 4 weighted average purchase price ($58.98); post-transaction value based on March 18, 2026 market close ($52.88).

Key questionsWhat proportion of Baker's holding was impacted by this trade?
The sale accounted for 12.52% of Baker's direct common stock holdings prior to the transaction. What is the context of Baker’s transactions?
The transactions were executed under a Rule 10b5-1 trading plan, allowing Baker to sell the shares in advance.

Today's Change

(

-2.04

%) $

-1.10

Current Price

$

52.88

Company overviewMetricValueRevenue (TTM)$609.78 millionNet income (TTM)$71.32 millionEmployees3191-year price change50.44%* 1-year price change calculated as of March 21, 2026.

Company snapshot The Vita Coco Company, Inc. develops and distributes coconut-based and functional hydration products, including coconut water, coconut oil, coconut milk, hydration drink mixes, sparkling water, plant-based energy drinks, purified water, and protein-infused fitness drinks. It targets health-conscious consumers in the United States, Canada, Europe, the Middle East, and the Asia Pacific, selling primarily through large retailers, convenience stores, and online platforms.

What this transaction means for investorsWith Baker’s sale of shares being part of a 105b-1 trading plan, the trade wasn’t an intentional sale in the moment, but for the COO, the sale came at a great time, as Vita Coco’s stock had a strong 2025, and on March 25, 2026, the stock may even spike higher. COCO will join the S&P SmallCap 600 prior to the opening of trading that day, replacing TEGNA Inc. (TGNA 1.26%), a media company acquired by Nexstar Media Group Inc. (NXST +1.49%), which was finalized on March 20. 

The addition to the SmallCap 600 could be highly beneficial for COCO, as ETFs tracking the index will have to purchase shares of the beverage company, potentially boosting the stock. And being on a major S&P index will provide the stock with greater visibility among institutional investors, analysts, and retail investors.

At the beginning of March, Vita Coco released a new flavor of its Vita Coco Treats product, frosted lemonade, as the weather around the U.S. starts to warm up. The Treats line is coconut milk-based beverages, different from its coconut water staple.

Kate Mitchell, Director of Ralliant (RAL 4.18%), reported an open-market purchase of 2,350 shares for a total consideration of ~$100,000, according to a SEC Form 4 filing dated Feb. 12, 2026.

Transaction summaryMetricValueShares traded2,350Transaction value$99,828.00Post-transaction shares (direct)0Post-transaction shares (indirect)8,411Transaction value based on SEC Form 4 reported price ($42.48).

Key questionsWhat was the structure and entity context of this transaction?
All 2,350 shares were purchased indirectly through The Wesley and Katherine Mitchell Living Trust, where Mitchell serves as trustee and beneficiary, with no shares acquired or held directly. How did this purchase impact Mitchell's overall ownership stake?
The acquisition raised the trust's position by 38.77%, increasing indirect holdings from 6,061 to 8,411 shares, while direct ownership remains at zero. Company overviewMetricValueRevenue (TTM)$2.07 billionNet Loss (TTM)$1.22 billionDividend yield0.20%Price (as of market close 3/21/26)$40.80

Today's Change

(

-4.18

%) $

-1.78

Current Price

$

40.77

Company snapshotRalliant provides advanced measurement and sensor technologies for defense and space applications. It designs and manufactures precision instruments, test and measurement systems, and specialty sensors. The company's strategy centers on innovation in precision measurement and sensor technology.

What this transaction means for investorsRalliant had a highly underwhelming Q4 FY 2025 earnings report on Feb. 4, 2026, reporting a $1.3 billion net loss, compared to $82.7 million in net income in the same period a year earlier. It was in large part due to a $1.4 billion goodwill impairment related to the acquisition of EA Elektro-Automatik, a power supplies company. EA’s book value exceeded its fair value, largely due to the subsidiary’s slower-than-anticipated growth and lowered expectations for electric vehicles, for which EA was supposed to be a significant contributor.

The dramatic turn in quarterly net income dropped Ralliant’s stock 31.8% in a single day to an all-time low on Feb. 5, reaching $37.27. This also caused the company to significantly lower its 2026 earnings outlook, leading to current investigations into whether Ralliant’s prior outlook, issued before the Q4 earnings, adequately prepared investors for the significant change in forecasts.

Ralliant’s institutional investors are pushing the company to engage in more stock buybacks and cost-saving initiatives. Irenic Capital Management, which currently owns 2% of Ralliant, is one of the investors who are pushing for those initiatives. Ralliant’s stock is in a difficult position, and investors interested in it should proceed with caution for now.

Adé Hennis has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Alibaba Group (BABA 1.90%) has spent the past few years navigating regulatory pressure, intense competition, and shifting investor sentiment. But as the company enters 2026, the picture is becoming clearer. The business is stabilizing in some areas while accelerating rapidly in others.

Based on recent earnings and industry trends, two developments are likely to define Alibaba's story in 2026.

Image source: Getty Images.

1. E-commerce growth will remain modest, and margins may stay under pressure Alibaba's core e-commerce platforms, Taobao and Tmall, are no longer the hypergrowth engines they once were. But they remain the company's foundation, generating the bulk of revenue and user engagement.

Recent results suggest the segment is stabilizing. In the quarter ending in December 31, 2025, Alibaba reported China commerce revenue growth of 6% year over year, driven mainly by the rapid expansion of quick commerce.

While the recent performance has improved compared to the last two years, investors should note that competition across China's e-commerce landscape remains fierce. Platforms such as Pinduoduo and Douyin continue to challenge traditional marketplaces with low-price strategies and short-video commerce experiences.

To defend its ecosystem, Alibaba has been investing heavily in improving customer mindshare through a stronger value proposition, enhanced services, and instant commerce. These initiatives help maintain user engagement but come at a cost. The company's earnings have come under pressure due to higher spending on quick commerce, user experience and technology.

Given these dynamics, a realistic scenario for 2026 is mid-to-high-single-digit growth in the e-commerce segment and continued margin pressure as Alibaba balances market share with profitability.

Today's Change

(

-1.90

%) $

-2.37

Current Price

$

122.53

2. AI will drive rapid expansion in Alibaba's cloud business While e-commerce stabilizes, a different growth story is unfolding within Alibaba's cloud division. Artificial intelligence (AI) is dramatically increasing the demand for computing infrastructure, and cloud providers are emerging as key beneficiaries of that trend. As a leading AI cloud computing player in China with more than 35% market share, Alibaba Cloud is already seeing the impact.

In the quarter ending in December 2025, the company reported cloud revenue growth of 36% year over year, driven largely by demand for AI-related services.

Even more telling, Alibaba disclosed that AI-related workloads have been growing at triple-digit rates for ten quarters! This shift is significant because AI applications require far more computing power than traditional cloud workloads. That dynamic is set to increase revenue per customer and strengthen the long-term economics of cloud platforms.

Alibaba has been investing aggressively to capture this opportunity, expanding data center capacity and developing its Qwen family of large language models, which enterprises can deploy through Alibaba Cloud.

With such a strong tailwind behind it, Alibaba Cloud is well positioned to deliver another year of high-double-digit growth in 2026.

What does it mean for investors? Alibaba's next chapter may look very different from its past. E-commerce is likely to remain stable but slower-growing, while cloud and AI increasingly drive the company's expansion.

For investors, that transition matters. Alibaba is gradually shifting from a pure e-commerce story to a broader technology platform built around cloud infrastructure and artificial intelligence.

If the two predictions above materialise, 2026 could further cement that transformation.

Sunrun delivers residential solar and battery storage solutions to U.S. homeowners through a direct-to-consumer model.

Key PointsPlusTick Management acquired 500,000 shares of Sunrun in the fourth quarter.

The quarter-end value of the new Sunrun position increased by $9.20 million, reflecting the new purchase.

The new Sunrun stake represents 4% of PlusTick Management LLC's 13F assets, placing it outside the fund's top five holdings.

PlusTick Management opened a new position in Sunrun (RUN 6.42%) during the fourth quarter, acquiring 500,000 shares worth $9.20 million, according to a February 17, 2026, SEC filing.

What happenedAccording to a filing with the Securities and Exchange Commission dated February 17, 2026, PlusTick Management initiated a new position in Sunrun by purchasing 500,000 shares. The quarter-end value of the stake increased by $9.20 million, which incorporates both the purchase and any price movement in the period.

What else to knowThis was a new position for PlusTick Management; the stake accounted for 4.07% of the fund's reportable assets as of December 31, 2025.Top holdings after the filing:NASDAQ: SATS: $39,675,500 (17.6% of AUM)NASDAQ: NN: $34,375,212 (15.2% of AUM)NASDAQ: APLD: $24,520,000 (10.8% of AUM)NASDAQ: INOD: $16,813,500 (7.4% of AUM)NASDAQ: NBIS: $11,300,175 (5.0% of AUM)As of Friday, Sunrun shares were priced at $12.22, up 82% over the past year and well outperforming the S&P 500’s roughly 15% gain in the same period.Company overviewMetricValuePrice (as of Friday)$12.22Market Capitalization$2.9 billionRevenue (TTM)$3 billionNet Income (TTM)($449.9 million)Company snapshotSunrun offers residential solar energy systems, battery storage, and related products, with revenue generated from system sales, installations, and ongoing maintenance services.The firm operates a direct-to-consumer business model, utilizing multiple sales channels including online, retail, field marketing, and partnerships to acquire and serve customers.It targets residential homeowners in the United States as its primary customer base.Sunrun delivers residential solar and battery storage solutions to U.S. homeowners through a direct-to-consumer model. Sunrun is a leading provider of residential solar and battery storage solutions in the United States, leveraging a large-scale direct sales network and diversified product offerings. The company’s strategy centers on expanding the adoption of distributed solar energy by providing end-to-end solutions, from system design through installation and maintenance. Sunrun’s integrated approach and strong brand presence position it as a key player in the transition to renewable energy for U.S. households.

What this transaction means for investorsSunrun delivered nearly $3 billion in revenue in 2025 and generated positive cash flow that it expects to continue this year. That is a meaningful pivot for a business that, not long ago, was defined by capital intensity and skepticism around profitability. At the same time, however, key metrics like subscriber growth and value creation have softened, suggesting the next phase will require tighter execution rather than just expansion. And that’s starting to reflect in the firm’s performance this year, with shares down 34% after this latest bout of earnings was released.

Within this portfolio, the position sits alongside smaller-cap, growth-oriented names, reinforcing the idea that this is a high-conviction but still opportunistic bet. It’s not the largest holding, but it is big enough to matter. Ultimately, it seems like Sunrun is starting to look like a scaled platform with real cash generation, which changes how investors should think about it.

About the Author

Jonathan Ponciano is a contributing stock market analyst at The Motley Fool. He has nearly a decade of experience as a financial journalist, most recently as an editor and senior reporter at Forbes focused on markets, technology, and entrepreneurship. Jonathan has also written for Investopedia and the Los Angeles Business Journal. He holds a dual B.A. in Business Journalism and Economics from the University of North Carolina at Chapel Hill and an M.B.A. from Columbia Business School. A North Carolina native now based in New York City, Jonathan has also lived in Mexico City and Los Angeles.

Investors typically think of Uber Technologies (UBER 1.93%) as a ride-hailing and food delivery company. And for good reason -- those businesses still drive the majority of its revenue and growth.

But beneath the surface, a quieter business is starting to take shape. And it could become one of Uber's most important profit drivers over time. That business is advertising.

A small segment with bigger-than-expected potential Uber's advertising business started as a simple idea: Help restaurants promote their listings within the Uber Eats app. For years, management viewed this as a useful but limited monetization tool.

In fact, the company once believed advertising penetration in delivery would top out at around 2% of gross bookings. But that assumption is already proving too conservative. On its latest earnings call, Uber said advertising penetration has already exceeded that 2% level (over $2 billion annualized revenue run rate), and the opportunity is now "much larger" than initially expected.

That shift matters. When management raises its view of a business's long-term potential, it often signals that early results are exceeding expectations. And in Uber's case, the drivers of that upside are becoming clearer.

Image source: Getty Images.

Why is advertising so powerful? Unlike rides or deliveries, advertising doesn't require drivers, vehicles, or logistics. It simply monetizes demand that already exists on the platform. That makes it a fundamentally different kind of business.

Every time a user opens the app to order food or request a ride, Uber has an opportunity to surface sponsored listings, promoted items, or targeted recommendations. These ads generate incremental revenue without adding meaningful cost.

As a result, advertising tends to carry significantly higher margins than Uber's core businesses. Note that Uber hasn't broken down the economics of its advertising business, but that's generally the case for businesses with high margins.

This is the same playbook that has worked for companies like Amazon, where advertising has become a multibillion-dollar, high-margin segment layered on top of its e-commerce platform. Uber appears to be moving in a similar direction.

The advantage Uber already has What makes Uber's advertising opportunity particularly compelling is the type of data it owns. Unlike traditional digital platforms, Uber operates in a transaction-driven environment. Users aren't just browsing; they are actively making decisions:

What to eat. Where to order from. How to get there. That creates strong commercial intent. On top of that, Uber has access to:

Real-time location data. Purchase history. Frequency of usage. Cross-platform behavior (mobility plus delivery). This allows the company to deliver highly targeted and relevant ads at the exact moment a user is ready to transact. That's a powerful combination for advertisers looking for a high return on investment.

Today's Change

(

-1.93

%) $

-1.45

Current Price

$

73.89

Still early, with multiple growth levers Importantly, Uber's advertising business is still in its early stages. Management highlighted that small and medium-sized businesses already have relatively high adoption. But enterprise advertising -- larger brands and chains -- is growing faster and still has significant room to scale. At the same time, advertising is likely to gradually expand beyond food delivery. Uber is beginning to roll out ad products across:

Grocery. Retail. Mobility. That last point is particularly interesting. If Uber can successfully integrate advertising into its ride-hailing experience -- for example, through in-app promotions or location-based recommendations -- it could unlock an entirely new monetization layer. And because these ads sit on top of existing transactions, they don't require Uber to significantly change its cost structure.

What this means for investors Uber's advertising business is unlikely to dominate revenue in the near term. But that's not the right way to think about it. The real impact is on profitability. High-margin revenue streams, such as advertising, can meaningfully lift overall margins, improve earnings quality, and make the business more predictable over time.

In other words, advertising doesn't just add revenue; it enhances the quality of earnings for the entire platform. For a company that already generates billions in free cash flow, that kind of incremental margin expansion could be especially valuable in creating long-term shareholder value.

NEW YORK, March 21, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Alight, Inc. (NYSE: ALIT) between November 12, 2024 and February 18, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 15, 2026.

SO WHAT: If you purchased Alight common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Alight class action, go to https://rosenlegal.com/submit-form/?case_id=54542 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 15, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose facts concerning the true state of Alight’s growth potential and financial stability; notably, that Alight was not truly equipped to execute on its claimed potential and could not maintain its promised dividend as a result. Rather, Alight would require significantly higher compensation and incentive expenses to achieve the projections put forth by management. Throughout the class period, defendants announced disappointing results, reduced projections, and multiple goodwill impairments all while remaining confident in their ability to execute, drive growth, and continue to provide a dividend to their shareholders. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Alight class action, go to https://rosenlegal.com/submit-form/?case_id=54542 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences (COGT 3.50%), an estimated $48.38 million trade based on quarterly average pricing.

What happenedAccording to a SEC filing dated February 17, 2026, Kynam Capital Management reduced its stake in Cogent Biosciences by 1,720,949 shares during the fourth quarter. The estimated transaction value was $48.38 million, calculated using the average closing price over the quarter. The quarter-end valuation of this position changed by $105.74 million, a figure that incorporates both share sales and stock price appreciation.

What else to knowKynam Capital Management, LP’s sell action left Cogent Biosciences at 13.99% of reported AUM after the trade.Top holdings after the filing:NASDAQ:COGT: $218.99 million (14.3% of AUM)NASDAQ:VERA: $173.85 million (11.3% of AUM)NASDAQ:SNDX: $169.15 million (11.0% of AUM)NASDAQ:CLDX: $161.42 million (10.5% of AUM)NASDAQ:PCVX: $134.84 million (8.8% of AUM)As of Friday, shares of Cogent Biosciences were priced at $33.38, up a staggering 360% over the past year, compared to a 15% gain for the S&P 500 in the same period.Company overviewMetricValuePrice (as of Friday)$33.38Market Capitalization$5.4 billionNet Income (TTM)($328.94 million)Company snapshotCogent Biosciences develops precision therapies targeting genetically defined diseases, with a lead product candidate (CGT9486) focused on inhibiting the KIT D816V mutation in systemic mastocytosis and advanced gastrointestinal stromal tumors.The company operates a research-driven biotechnology business model, generating value through the clinical development and potential commercialization of proprietary therapies, supported by licensing agreements such as that with Plexxikon Inc. for bezuclastinib.It targets patients with rare, genetically defined cancers and systemic mastocytosis, primarily serving healthcare providers, research institutions, and specialty treatment centers.Cogent Biosciences, Inc. is a clinical-stage biotechnology company specializing in the development of targeted therapies for genetically defined diseases. The company leverages precision medicine to address unmet medical needs in rare cancer populations, with a strategic focus on selective kinase inhibition. Its approach positions it at the forefront of innovation in the biotechnology sector, aiming to deliver differentiated solutions for patients with limited treatment options.

What this transaction means for investorsCogent has clearly become one of biotech’s hottest stocks. Even after this $48 million trim, it still sits at roughly 14% of assets, making it the fund’s single largest position. That tells you everything about how conviction and risk are being balanced here. The trim reins in exposure without disrupting a core thesis that is still very much intact.

The company’s bezuclastinib received FDA acceptance earlier this month based on positive clinical results from the SUMMIT pivotal trial, in which the product showed a clear clinical benefit across all symptom domains in patients with non-advanced systemic mastocytosis. The FDA assigned a target action date of December 30. Last month, the firm reported ending the year with $900.8 million in cash and cash equivalents, enough to fund operations into 2028. All of that to say this sale looks almost surely tied to discipline as opposed to a loss of conviction, and several catalysts will ultimately determine how this rally shapes out.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

After becoming the first healthcare stock to hit a $1 trillion market valuation in late 2025, Eli Lilly (LLY 1.29%) hasn't performed well since, with its shares down about 19% from their 52-week high of $1133.95. Some are worried about the company's runaway valuation, while others fear that, even as the drugmaker leads the market for weight management medicines, increased competition will erode its pricing power and depress its profits and margins. The bulls might have a different view, though, but which side is right?

Image source: Getty Images.

The expanding anti-obesity market While it's true that there will be more competition in chronic weight management, Eli Lilly's lead in this space seems safe. What's more, newer launches will help the company solidify its top position while expanding its addressable market. Take orforglipron, an oral GLP-1 candidate Eli Lilly is gearing up to launch, hopefully in the second quarter. As management noted, the only oral therapy currently approved for weight loss, oral Wegovy, is attracting new patients, likely those who did not want to take older subcutaneous weight-loss medications.

Orforglipron could be a best-in-class medicine thanks to its strong clinical trial performance across both diabetes and obesity, including some studies in which it went head-to-head with other oral GLP-1s and performed better. Eli Lilly could also target an underserved niche with another candidate, retatrutide. In a phase 3 study, not only did retatrutide lead to an outstanding 28.7% mean weight loss after 68 weeks -- a number never before seen in a phase 3 clinical trial -- but it also significantly reduced knee pain.

Eli Lilly will target patients with high body mass indexes -- for whom current weight-loss options often plateau, leaving them with plenty of work to do -- with this drug.

Today's Change

(

-1.29

%) $

-11.87

Current Price

$

905.63

Beyond weight management But what if, even as it expands and Eli Lilly maintains its lead in it, the market for anti-obesity medicines doesn't reach the peaks some analysts anticipate? Eli Lilly is prepared for that scenario. Unlike its biggest rival, Novo Nordisk, Eli Lilly has billion-dollar drugs right now -- and likely others that will follow -- outside its core therapeutic area. The company's lineup includes medicines such as Verzenio, a cancer drug that generated $5.7 billion in sales last year, up 8% year over year.

Eli Lilly's Taltz, an immunosuppressant, grew its sales 9% year over year to $3.6 billion. True, their contributions pale in comparison to Eli Lilly's diabetes and obesity products, but that's why the company has been aggressively expanding beyond weight management. Eli Lilly now has a deep pipeline of candidates -- some acquired through licensing deals -- across many fields, including pain management, oncology, and immunology.

Meanwhile, Eli Lilly trades at 27x forward earnings, compared to the healthcare sector's average of 17.1x. Is Eli Lilly worth the premium? Considering it has been growing its revenue and earnings much faster than its similarly sized peers and still has a deep pipeline that should help power growth in the medium term, I think it is. The stock looks attractive right now.

For several months, I had been warning investors that SoFi (SOFI 0.85%) stock was too expensive. Since my warnings, the stock has crashed to lower levels.

*Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026.

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Reddit (RDDT +1.43%) is one of the fastest-growing social media companies in the world.

*Stock prices used were the afternoon prices of March 19, 2026. The video was published on March 21, 2026.

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Reddit. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Apple's (AAPL 0.38%) past is defined by its winning performance. Shares have skyrocketed a jaw-dropping 953%, including dividends, in the last decade (as of March 17). This is impressive given the scale of the business. Investors are now targeting the next milestone.

Is this "Magnificent Seven" stock going to $500? Here's what has to happen for Apple's share price to effectively double over the next five years.

Image source: The Motley Fool.

Apple's profit growth needs to pick up Between fiscal 2022 and fiscal 2025 (ended Sept. 27, 2025), Apple's diluted earnings per share (EPS) rose at a compound annual rate of 6.9%. Over the next three fiscal years, the consensus view among sell-side analysts is that this figure will expand at a yearly clip of 11.4%. This is a very upbeat outlook compared to recent history.

But there's a chance that forecast doesn't play out, as a company of this magnitude naturally starts to see slower growth. And I still believe Apple's diluted EPS must increase at a faster clip than the 11.4% estimate for the stock to have a chance at hitting $500 in five years.

The latest financial results are promising, though. During the first quarter of fiscal 2026 (ended Dec. 27, 2025), Apple's revenue jumped 15.7% year over year, driven by a robust 23.4% gain for the iPhone. This drove diluted EPS 18.3% higher.

Apple can certainly have single quarters of strong growth that coincide with innovation cycles. For what it's worth, it just announced a fresh lineup of new products that can drive consumer excitement and upgrade activity in the near term.

However, I don't believe the latest outsize gains represent a new normal of what investors should expect. On an annualized basis in Q1, Apple's revenue base totaled a whopping $575 billion. It becomes more difficult to move the needle at that size.

Today's Change

(

-0.38

%) $

-0.95

Current Price

$

248.00

Market sentiment must remain healthy Apple shares are taking a breather. They trade 11% below their record from December last year. The valuation is still not indicative of a bargain opportunity. The price-to-earnings (P/E) ratio sits at 32.2.

If investors want the stock price to reach $500 by 2031, that multiple probably needs to expand. Improving market sentiment, as demonstrated by a higher valuation, can be a powerful force for investment returns.

I wouldn't bet on this happening, though. If Apple's growth decelerates in the future, it probably justifies a lower P/E ratio. Perhaps the stock deserves to ultimately trade at a multiple between 25 and 30. This adds downside risk to the investment thesis.

Given the likelihood that diluted EPS rises at a high-single-digit or low-double-digit pace per year, coupled with the possibility that Apple's valuation ratio contracts, I'm not confident that this stock will get to $500 in five years. But over a slightly longer time horizon, that outcome seems much more probable.

For years, Tesla (TSLA 3.33%) has had much of the U.S. EV market to itself. There's a reason why Tesla's market cap is well above $1 trillion, while most other EV stocks are valued at less than $20 billion. Tesla controls more than half of the U.S. EV market, a commanding market position fueled by its most popular vehicle: the Model Y.

The Model Y represents more than 70% of Tesla's vehicle sales. But next month, the Model Y will have a new competitor: Rivian's (RIVN 7.44%) R2 SUV. How scared should Tesla investors be? And how bullish should Rivian investors be? The answer is more surprising than you'd expect.

Today's Change

(

-7.44

%) $

-1.20

Current Price

$

14.92

Expect Rivian to eat into Tesla's market share Tesla's Model Y, a crossover design, was the top-selling EV in 2025. An estimated 317,800 units were sold last year. The next top-selling model was Tesla's Model S, a sedan. The rest of the top-selling EVs of 2025 have something in common: Most are SUVs. Tesla's Model S is the only sedan to crack the top 10. Tesla's Model Y is the only crossover. There are two full-sized trucks, too. But the rest of the list -- a total of six out of 10 -- are SUVs.

Notably, Tesla does have an SUV on the market: its luxury Model X vehicle. But that vehicle's starting price of $90,000 is a non-starter for most vehicle buyers. Plus, CEO Elon Musk revealed earlier this year that Tesla will likely discontinue all production of that model.

In total, we can glean two things from this information. First, car buyers love buying Teslas. Second, car buyers love buying SUVs. And yet Tesla doesn't have an affordable SUV in its lineup. The Model Y -- a crossover -- is as close as it gets, which is likely why that model is so successful. Producing an affordable SUV is more difficult than producing an affordable crossover, however, as SUVs are typically larger, requiring more raw materials and factory work to produce. But starting next month, Rivian is expected to start deliveries on what I consider the holy grail of EVs in the U.S.: a feature-packed, long-range SUV priced under $50,000.

It's not hard to put the pieces together. Tesla's vehicle sales rely heavily on Model Y sales. And next month, Tesla will arguably face its stiffest competition yet in the form of Rivian's R2 SUV. This should be good news for Rivian and bad news for Tesla. But there's a chance that more competition for Tesla's Model Y will hurt the company's prospects less than you might think.

Image source: Rivian.

Tesla's valuation won't hinge on Model Y sales Take a look at Tesla's valuation and you'll quickly realize that its $1.2 trillion market cap isn't predicated on its auto manufacturing business. Tesla's auto volumes fell for the first time in 2025, and analysts aren't confident that a turnaround will arrive anytime soon. And yet Tesla's share price continues to hit new highs. Why? Because the market doesn't view this legacy business as critical for Tesla's future prospects.

"Tesla is 'entering a transition phase,'" observes a recent report from Reuters, "where it is asking investors to underwrite potential revenue from self-driving software in its cars and robotaxi business before auto sales recover." In short, the market is now valuing Tesla as an artificial intelligence (AI) and autonomous driving stock, not a manufacturing business. The robotaxi market alone, which Tesla intends to compete in heavily, could be worth $5 trillion to $10 trillion over the long term. If Tesla succeeds in capturing that opportunity, the decline of its legacy auto business will be fairly easy to stomach.

Oddly enough, both Rivian and Tesla have room to succeed. Rivian stands to gain market share at Tesla's expense, while Tesla has the chance to target markets far bigger than its current sales footprint. So yes, Tesla has reason for concern when it comes to Rivian's R2 launch. But that one challenge won't make or break the company's current valuation, which incorporates far more than just auto sales.

Shares of Scholastic (SCHL +8.82%) rose this past week after the children's education and media leader's quarterly results earned higher marks than investors expected.

According to data from S&P Global Market Intelligence, Scholastic's stock price was up more than 10%.

Image source: Getty Images.

Q3 earnings beat Scholastic's revenue declined by 2% year over year to $329.1 million in its fiscal 2026 third quarter, which ended on Feb. 28.

The timing of publishing releases led to a 3% decrease in children's book publishing and distribution sales to $197.6 million. Continued funding challenges for school districts drove a 2% decline in education revenue to $56.1 million. These shortfalls were partially offset by a 25% jump in entertainment sales to $16 million.

All told, Scholastic produced an adjusted loss per share of $0.15. That was significantly better than Wall Street expected. Analysts had forecast a per-share loss of $0.37.

Today's Change

(

8.82

%) $

3.02

Current Price

$

37.26

Rising capital returns for shareowners Scholastic has focused on reducing its cost structure to mitigate the effects of sluggish sales. The company raised over $400 million from the sale of its headquarters in New York City and its distribution center in Jefferson City, Missouri.

Scholastic used the proceeds to pay down debt and bolster its cash reserves, while also buying back more than $147 million of its shares. Its board of directors also approved a $200 million tender offer as part of a new $300 million share repurchase program.

These repurchases, along with Scholastic's dividend payments, will be supported by a projected $430 million in full-year free cash flow.

"We remain focused on maximizing shareholder value, disciplined execution, and accelerating profitability, as we position the company for growth in fiscal 2027 and fulfill our mission to help children read, learn, and thrive," CEO Peter Warwick said.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - March 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Aquestive class action, go to https://rosenlegal.com/submit-form/?case_id=55756 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 4, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose the true state of Aquestive's New Drug Application ("NDA") for Anaphylm; pertinently, Aquestive concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Aquestive class action, go to https://rosenlegal.com/submit-form/?case_id=55756 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289356

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Irvine, CA, March 21, 2026 (GLOBE NEWSWIRE) -- Vemanti Group, Inc. ("Vemanti" or the "Company") (OTC: VMNT) announced today that it is aware that the ONUS Pro platform (the "Platform") has experienced a significant service disruption affecting users' ability to access their accounts and funds.

The Company has received complaints from Platform users who are unable to access their accounts and funds. The Company takes these complaints very seriously and is treating this matter with the highest priority. As a parent holding company without direct access to the Platform's systems, the Company is unable to intervene directly on behalf of affected users, but its executive team is working urgently to establish contact with the appropriate personnel at the Platform and will provide further updates as information becomes available.

The Company owns 100% of XPLOR Technology Pte. Ltd. ("XPLOR"), the Singapore-based parent company of the Platform. The Company completed its acquisition of XPLOR on October 29, 2025. However, all day-to-day operations pertaining to the Platform, including user accounts and transaction systems, are outsourced and managed by Onus Labs Technology, JSC ("Onus Labs"), a Vietnam-based entity. Onus Labs is not owned by XPLOR or the Company.

About Vemanti

Vemanti Group, Inc. is a diversified technology holding company with a focus on the emerging markets of Southeast Asia. The Company operates across various sectors of leading-edge digital financial services and seeks growth through strategic partnerships, joint ventures, or mergers and acquisitions. By leveraging synergies and complementary strengths of these relationships, we look to diversify and expand our market reach. Ultimately, as a publicly traded company, we're committed to creating long-term value for our shareholders while actively seeking out new opportunities. Learn more at: https://vemanti.com

About XPLOR

XPLOR Technology Pte. Ltd. is a technology-focused holding company based in Singapore, managing a portfolio of next-generation financial technology ventures. The company is dedicated to harnessing trend-setting technology to redefine the financial landscape. It invests in and supports projects that push the boundaries of digital finance, focusing on scalability, security, and user-centric innovations. With a strong approach to integrating advanced technological solutions across its subsidiaries, XPLOR ensures that each entity is well-equipped to lead in their respective markets, driving progress and profitability in the dynamic fintech sector.

About Onus Pro

ONUS Pro is a leading digital asset exchange platform serving Southeast Asia. Known for its user-friendly interface and strong community-driven growth, ONUS Pro provides cryptocurrency trading, investment, and blockchain-based financial services to millions of users. ONUS Pro offers a complete ecosystem of investment products, with access to more than 600 digital assets.

Legal Disclaimer

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filing with the Securities and Exchange Commission (“SEC”) prior to January 23, 2025. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s filings with the SEC prior to January 23, 2025. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact Information

Vemanti Group, Inc.
Investor Relations
+1.949.559.7200
[email protected]

DAFNA Capital Management reported a buy of 720,000 shares of Biohaven (BHVN 0.22%) in a February 17, 2026, SEC filing, with the estimated transaction value at $8.92 million based on quarterly average pricing.

What happenedAccording to a February 17, 2026, SEC filing, DAFNA Capital Management increased its position in Biohaven by 720,000 shares during the fourth quarter of 2025. The estimated value of this trade was $8.92 million, based on quarterly average pricing. The stake’s total value at quarter-end was $10.78 million, up $7.25 million from the previous period, a change reflecting both the additional shares and movements in the stock’s price.

What else to knowDAFNA’s Biohaven position now represents 2.51% of its reportable U.S. equity assets after this buy.Top five holdings after the filing:NASDAQ:RVMD: $48.15 million (11.3% of AUM)NYSEMKT:XBI: $41.03 million (9.7% of AUM)NYSEMKT:STXS: $31.47 million (7.4% of AUM)NASDAQ:ATRC: $23.63 million (5.6% of AUM)NASDAQ:CYTK: $23.57 million (5.5% of AUM)As of Friday, Biohaven shares were priced at $8.93, down a staggering 68% over the past year and significantly underperforming the S&P 500, which is instead up about 15% in the same period.Company overviewMetricValuePrice (as of Friday)$8.93Market Capitalization$1.3 billionNet Income (TTM)($738.8 million)Company snapshotBiohaven develops clinical-stage therapies targeting neurological and immunoscience diseases, with no commercialized products or revenue as of the latest reporting period.The firm operates a research-driven business model, generating value through the advancement of its proprietary pipeline toward regulatory approval, and potential future commercialization or partnerships.Its primary customers are expected to be healthcare providers, hospitals, and specialty clinics treating neurological and immune-related conditions once products reach the market.Biohaven is a biotechnology company focused on the development of novel therapies for neurological and immunoscience disorders. The company leverages its scientific expertise to advance a pipeline of clinical-stage assets, aiming to address unmet medical needs and improve patient outcomes. With a strategic emphasis on innovation and potential market disruption, Biohaven seeks to establish a competitive edge through differentiated science and targeted indications.

What this transaction means for investorsThis is the kind of move that only makes sense if you believe the story is about what happens next, not what just happened. Biohaven’s stock is down nearly 70% over the past year, but the underlying company has quietly reshaped itself around a much tighter set of priorities.

That comes as management makes important moves, cutting spending, narrowing its focus to three late-stage programs, and pushing toward a cluster of meaningful readouts this year, including epilepsy, immunology, and obesity. That shift matters more than the headline losses. The company still posted a net loss of roughly $739 million last year, but that number reflects a business in transition rather than one standing still.

And of course, liquidity also buys time. With about $322 million in cash at year-end and additional capital raised after, the runway looks more stable than the share price implies. Ultimately, in the context of a portfolio already loaded with higher-conviction biotech names, this position reads like optionality. It is not a core bet, but a calculated swing at asymmetric upside if even one of those late-stage programs delivers.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool recommends SPDR Series Trust - SPDR S&P Biotech ETF. The Motley Fool has a disclosure policy.

Elizabeth, NJ, March 21, 2026 (GLOBE NEWSWIRE) -- This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This report is an informational overview and does not constitute medical, health, or dermatological advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

In this report, the term "effectiveness" refers strictly to how the product's marketing language describes potential outcomes. It does not indicate that the finished product has been clinically proven effective, and no published clinical trial appears to evaluate Akemi Hair Glow as a proprietary formula.

As consumer interest in topical hair growth solutions continues to grow, Akemi Hair Glow has become one of the products generating attention across social media platforms and wellness communities. The product is marketed primarily toward women experiencing thinning hair, increased shedding, or visible scalp areas that have become harder to conceal over time.

The product's claims around DHT blocking, follicle reactivation, and "56% thicker hair in 18 weeks" have contributed to that visibility. These types of claims are common in the topical hair growth category and are presented in this report alongside published ingredient-level research for contextual reference.

This report presents how the product is described alongside relevant research considerations. It outlines what the product page states, what published ingredient-level research supports under controlled study conditions, and where gaps remain between the marketing language and clinical evidence for the finished product.

Current product details, pricing, and terms can be confirmed by viewing the current Akemi Hair Glow offer (official Akemi Hair Glow page).

Individual results vary. Topical hair products are not substitutes for professional dermatological evaluation, balanced nutrition, or medical treatment for diagnosed hair loss conditions. Consult a qualified healthcare provider before starting any new topical hair regimen, especially if you are experiencing sudden or severe hair loss.

What Is Akemi Hair Glow

Akemi Hair Glow is a topical hair spray positioned as a DHT-blocking formula designed to support hair growth, reduce shedding, and improve hair thickness and texture. The product is sold exclusively through its official website, which operates on a Shopify-based platform under the domain buyskyline.co. The product page describes it as a leave-in daily treatment that delivers active ingredients directly to the scalp rather than through oral ingestion.

The product page lists six primary active ingredients: Biotin (Vitamin B7), Aminexil, Castor Oil, Caffeine, He Shou Wu (Fo-Ti), and Ginger Root Extract. The formula is described as free from parabens and toxins, with natural preservatives. The specific concentrations of each ingredient per application are not disclosed on the product page or in publicly available materials.

Per the FAQ section on the official website, orders ship from a New Jersey-based warehouse via USPS, FedEx, UPS, or DHL for international customers. The site states that products ship within 48 business hours, with standard delivery taking between five and seven days.

How Akemi Hair Glow Describes Its DHT-Blocking Mechanism

The product page centers its marketing narrative on DHT (dihydrotestosterone) as the primary driver of hair loss, particularly in women. The sales page describes DHT as a hormone that attacks hair follicles, shrinks them over time, and eventually causes them to stop producing hair entirely. The product is positioned as a formula that neutralizes DHT directly at the scalp.

The report presents what published dermatological research supports about that underlying mechanism, and where the product's marketing language extends beyond the evidence currently available for this specific formula.

DHT's role in androgenetic alopecia (pattern hair loss) is well established in published research. DHT is a metabolite of testosterone produced by the enzyme 5-alpha reductase. In genetically susceptible individuals, DHT binds to androgen receptors in hair follicles, triggering miniaturization — a process in which follicles progressively shrink and produce thinner, shorter hairs until they eventually stop producing visible hair. This mechanism is recognized across published dermatological literature as a primary contributor to pattern hair loss in both men and women.

The underlying science connecting DHT to hair loss is well documented. The question the report addresses is whether this specific spray, at its undisclosed ingredient concentrations, delivers DHT-blocking activity at levels sufficient to produce the results described on the product page.

Among the listed ingredients, caffeine has the most directly relevant published research regarding DHT interaction at the follicular level. A 2007 study published in the International Journal of Dermatology found that caffeine counteracted testosterone-suppressed hair growth in vitro — meaning in laboratory conditions using human hair follicles. A separate 2018 multicenter clinical study published in Skin Pharmacology and Physiology reported that a 0.2% caffeine-based topical liquid performed comparably to 5% minoxidil solution over six months in men with androgenetic alopecia. A February 2025 systematic review analyzing multiple clinical trials concluded that caffeine can stimulate cell growth and effectively penetrate hair follicles, positioning it as a promising topical agent against hair loss.

Those are meaningful findings. However, every one of those studies tested caffeine at disclosed concentrations under controlled conditions — not this specific multi-ingredient spray at undisclosed concentrations. The report references this research to provide context, not to confirm that Akemi Hair Glow replicates these study conditions.

He Shou Wu (Fo-Ti) is described on the product page as an ingredient that inhibits DHT production while stimulating dormant follicles. He Shou Wu has a long history in traditional Chinese medicine, and some in vitro studies have explored its effects on 5-alpha reductase activity. However, robust clinical trials specifically evaluating topical He Shou Wu for DHT blocking in human hair loss are limited in the published literature.

This is ingredient-level research context. Akemi Hair Glow as a finished product has not been evaluated in any published clinical trial appearing in peer-reviewed journals.

The "56% Thicker Hair in 18 Weeks" Claim: What the Data Trail Shows

The product page prominently states that customers see "56% thicker, fuller hair in just 18 weeks." This figure appears alongside the name "Dr. Sarah Mitchell, Certified MD & Published Medical Author."

The report outlines several questions about the evidence trail behind that number that consumers may want to consider before making a purchasing decision.

The source methodology behind the 56% figure is not disclosed on the product page. The site does not specify whether this number comes from a controlled clinical study, an internal consumer survey, instrument-measured trichoscopy data, or another methodology. Without knowing how the measurement was taken, what baseline was used, what sample size was involved, and whether a placebo control was included, the figure cannot be independently compared against published hair growth research standards.

The association with "Dr. Sarah Mitchell" is presented without a linked publication, institutional affiliation, or verifiable credential trail on the product page. Consumers researching this endorsement may want to verify the clinician's credentials independently before weighting the claim.

For context, published clinical research on topical caffeine — one of the listed ingredients — has measured outcomes such as anagen-to-telogen hair ratios, hair density counts, and hair pull test improvements over periods of three to six months. These studies report improvements using standardized trichogram measurements. A claim of "56% thicker hair" would represent a notably strong result if measured by those clinical standards. That does not mean the claim is false — it means the methodology matters, and that methodology is not publicly available.

The product page also references a "93% success rate" and a "95% success rate" in different sections of the same page and describes "3,758 Reviews," "3,000+ Verified Reviews," and "4,000+ satisfied users" in different locations. These inconsistencies across the same product page are worth noting when forming an assessment of the company's published statistics.

Akemi Hair Glow Ingredient Profile: What Published Research Supports at the Compound Level

The product page lists six primary active ingredients. The report outlines what published research supports at the individual ingredient level — and why the distinction between ingredient research and finished-product evidence matters when evaluating this type of product.

Biotin (Vitamin B7): Biotin is one of the most widely marketed hair growth ingredients. However, a 2024 systematic review published in the Journal of Clinical and Aesthetic Dermatology examined published clinical studies specifically on biotin for hair growth and found that the highest-quality study — a double-blind, placebo-controlled trial — showed no difference between the biotin and placebo groups for hair growth. The review concluded that a significant gap exists between public perception of biotin's effectiveness and what the scientific literature actually demonstrates. Akemi Hair Glow uses topical rather than oral biotin, and the product page suggests this delivery method bypasses digestive limitations. Limited published data exists on topical biotin specifically for hair growth outcomes.

Caffeine: Among the listed ingredients, caffeine has the strongest published clinical evidence for topical hair applications. In vitro research demonstrated that caffeine counteracts DHT-induced hair follicle miniaturization and stimulates follicle proliferation. A clinical study found that a 0.2% caffeine topical performed comparably to 5% minoxidil over six months. A 2025 systematic review further supported caffeine's potential as a topical hair loss agent while noting that most studies suffered from methodological limitations and significant gender imbalance — only 4.4% of study participants were women, despite hair loss products frequently targeting female consumers. The concentration of caffeine in Akemi Hair Glow is not disclosed, making direct comparison to published study dosages impossible.

Aminexil: The product page describes aminexil as an anti-fibrosis molecule that prevents DHT from stiffening tissue around follicles. Aminexil was originally developed and studied primarily by L'Oréal for their Dercos line. Published research has explored its potential to prevent collagen hardening around hair follicles, which can contribute to permanent hair loss. The published research base is more established than that of some cosmetic hair ingredients, though independent replication outside company-sponsored studies remains limited.

Castor Oil: Castor oil is a traditional hair care ingredient valued for its moisturizing properties. Ricinoleic acid in castor oil has demonstrated anti-inflammatory properties in published research. However, clinical evidence specifically connecting topical castor oil application to measurable hair regrowth is sparse. Most evidence supporting castor oil's hair benefits comes from traditional use and mechanistic reasoning rather than controlled clinical trials.

He Shou Wu (Fo-Ti): This traditional Chinese medicinal herb has been used for centuries for hair-related concerns, including premature graying and hair loss. Some in vitro research has explored its effects on 5-alpha reductase activity and hair follicle cell proliferation. Clinical evidence for topical He Shou Wu in human hair growth remains limited. Additionally, oral He Shou Wu preparations have been associated with hepatotoxicity concerns in published case reports, though topical application presents a different risk profile.

Ginger Root Extract: Ginger has published evidence supporting anti-inflammatory and circulatory-boosting properties. Improved scalp microcirculation can theoretically support healthier follicle environments. However, one study published in the Journal of Dermatological Science suggested that 6-gingerol, an active compound in ginger, may actually suppress hair growth in certain contexts. The relationship between ginger and hair growth appears more nuanced than the product's marketing suggests.

These are individual ingredient findings from published research. They do not represent clinical outcomes for Akemi Hair Glow as a finished formula, and individual experiences differ based on the type and cause of hair loss, genetics, hormonal factors, and consistency of use.

Topical Delivery: Does the Spray Format Offer a Research-Supported Advantage

The product page emphasizes that topical application delivers ingredients "directly to your follicles" rather than having them "dissolved in stomach acid where 97% of supplements get destroyed." This positioning is central to how the product differentiates itself from oral hair supplements.

Published evidence supports the general principle that hair follicles serve as an effective penetration pathway for topically applied substances. Research published in the British Journal of Clinical Pharmacology demonstrated that caffeine penetrates hair follicles rapidly when applied topically and that follicular accumulation of caffeine can be significantly higher than in surrounding skin tissue. For topical caffeine specifically, the delivery advantage has a documented scientific basis.

The "97% destroyed in stomach acid" claim, however, oversimplifies digestive pharmacology. Oral bioavailability varies dramatically between compounds. Biotin, for example, is well absorbed orally — it has high oral bioavailability, which makes the blanket claim misleading when applied to that specific ingredient.

The more practical question is whether these specific ingredients, at their undisclosed concentrations, penetrate the scalp in sufficient quantities to produce the effects described on the product page. Without disclosed ingredient concentrations, this question cannot be answered from publicly available information.

Pricing, Guarantee, and Purchase Details

The product page includes promotional pricing ranges and inventory-related messaging that may vary over time and are determined by the company. At the time of this report, the site references "up to 50% off" and "up to 60% off" in different sections of the same page. Specific pricing tiers are presented during checkout.

The product page describes a 30-day money-back guarantee. The FAQ section states: "Simply return your product and we'll give you a refund for 30 days." However, the Terms of Service page includes a disclosure about a minimum 15% restocking fee for returns. This gap between the marketing presentation and the published terms is worth clarifying directly with the company before ordering.

The Terms of Service identify the operator as "Akemi Hair Glow" and reference New York for certain legal proceedings, while the Governing Law section references the laws of Florida.

Verify current pricing, refund terms, and restocking fee details before purchasing by viewing the current Akemi Hair Glow offer (official Akemi Hair Glow page).

What the Product Page Presents as Customer Feedback

The official website includes customer testimonials describing outcomes such as visible new hair growth at the crown and temples, reduced shedding, bald patches filling in, and hair texture improvements within specific timeframes. These testimonials are attributed to named individuals with locations.

The company does not disclose whether these testimonials reflect typical outcomes or controlled evaluation conditions. The site does not describe how testimonials are collected or verified, or whether any compensation or incentive is provided. People who write reviews are self-selected — satisfied customers are significantly more likely to post feedback than those with neutral or negative experiences.

Testimonial results are individual experiences and should not be interpreted as typical or guaranteed outcomes. Published research on hair growth interventions consistently shows that individual outcomes depend on the specific type and cause of hair loss, genetic factors, hormonal profiles, and treatment consistency.

Consumer Considerations Based on Product Characteristics

This section outlines general considerations based on the product's described characteristics and publicly available ingredient research. It is not intended to recommend the product for any individual use case.

Consumers evaluating topical products may consider Akemi Hair Glow if they:

Prefer topical over oral approaches. Consumers who have tried oral hair supplements without satisfaction or who prefer applying active ingredients directly to the scalp may find a spray format aligns with their preference. Published research on topical caffeine shows promising follicular penetration and, in at least one clinical study, comparable performance to topical minoxidil.

Are exploring complementary options alongside professional care. Consumers already working with a dermatologist and looking for an additional daily topical may note that ingredients like caffeine and aminexil have published research supporting their potential roles in hair maintenance as part of a broader approach.

Want a non-prescription starting point. For consumers not yet ready for prescription options like minoxidil or finasteride, a botanical-based spray may serve as an entry point while evaluating whether professional intervention is appropriate for their specific situation.

Other options may be preferable for consumers who:

Require transparent ingredient dosing. Consumers who need exact ingredient concentrations for comparing against published research dosages should note that those amounts are not disclosed for this product.

Are experiencing sudden or severe hair loss. Rapid, sudden, or patchy hair loss may indicate medical conditions such as alopecia areata, thyroid disorders, or nutritional deficiencies that require professional diagnosis and treatment rather than a topical cosmetic product.

Expect results comparable to FDA-approved treatments. Published clinical data for FDA-approved treatments like minoxidil represents a different evidence standard than what is currently available for this proprietary formula.

Questions to consider before purchasing: What type of hair loss am I experiencing, and has a healthcare professional evaluated the cause? Have I researched the specific ingredients at the concentrations used in published studies? Am I comfortable purchasing a product without disclosed ingredient concentrations? Have I reviewed the full refund terms, including the potential restocking fee? These questions can help determine whether this product's characteristics match a consumer's specific situation.

Verification Checklist: What to Confirm Before Ordering

Verify ingredient concentrations. Individual ingredient amounts per application are not disclosed. If dosing relative to published research matters to the purchasing decision, contact the company directly to request this information.

Separate ingredient research from product research. Published studies on caffeine, biotin, aminexil, and other listed ingredients examined those compounds individually under controlled conditions. No published clinical trial appears to evaluate Akemi Hair Glow as a finished proprietary formula.

Trace the "56% thicker hair" claim. The methodology behind this figure is not publicly disclosed. Without understanding the measurement approach, sample size, and control conditions, the number cannot be independently verified against clinical standards.

Review the refund terms carefully. The product page describes a 30-day money-back guarantee, but the Terms of Service disclose a potential 15% restocking fee. Clarify exact refund terms before purchasing.

Consult a healthcare provider. This is especially important for women experiencing hair loss related to hormonal changes, thyroid conditions, nutritional deficiencies, or medical treatments. A dermatologist can help identify the underlying cause and recommend evidence-based interventions. This report is not a substitute for professional dermatological evaluation.

Consumer Questions About Akemi Hair Glow

What is DHT, and why does it matter for hair loss?

DHT (dihydrotestosterone) is a hormone derived from testosterone that plays a recognized role in androgenetic alopecia (pattern hair loss). In genetically susceptible individuals, DHT causes hair follicle miniaturization over time. This mechanism is well established in published dermatological research. However, not all hair loss is DHT-related — conditions such as telogen effluvium, alopecia areata, and nutritional deficiency-related hair loss involve entirely different mechanisms.

Is Akemi Hair Glow a medication or FDA-approved product?

Akemi Hair Glow is marketed as a topical cosmetic hair spray, not a medication. It is not FDA-approved for the treatment of any medical condition. The product has not undergone the clinical trial process required for FDA drug approval. Consumers seeking FDA-approved treatments for hair loss should discuss options such as topical minoxidil or oral finasteride with a qualified healthcare provider.

How does the caffeine in this product compare to what has been studied clinically?

Published clinical research has tested topical caffeine at disclosed concentrations — for example, a 0.2% caffeine-based topical that performed comparably to 5% minoxidil over six months. Akemi Hair Glow's caffeine concentration is not disclosed, which makes direct comparison to published study dosages impossible. These are different products with different evidence bases, even though they share a common ingredient.

Will this product address my type of hair loss?

The product's marketing focuses on DHT-related hair thinning. If hair loss has a different underlying cause — such as thyroid dysfunction, iron deficiency, autoimmune conditions, or medication side effects — a topical DHT-blocking spray may not address the underlying issue. A healthcare professional can help determine the cause and recommend appropriate interventions.

How long before results might be noticed?

The product page describes a week-by-week timeline suggesting changes beginning at week 2 and continuing through week 16. Published research on topical hair growth interventions generally suggests that meaningful results, when they occur, typically require three to six months of consistent use. Individual timelines depend on factors including the type of hair loss, its severity, and individual biological response. The timeline descriptions on the product page represent the company's marketing positioning rather than clinically validated benchmarks for this specific product.

What should consumers know about the return policy before ordering?

The product page describes a 30-day money-back guarantee. The Terms of Service page discloses a potential minimum 15% restocking fee for returns. The exact refund process, applicable fees, and return shipping requirements should be confirmed directly before purchasing. Complete terms are available by viewing current Akemi Hair Glow terms (official Akemi Hair Glow page).

Summary of Key Considerations

Akemi Hair Glow is a topical hair spray positioned around DHT-blocking and follicle reactivation claims. The product contains ingredients — particularly caffeine — with published research at the individual compound level supporting potential hair growth benefits when applied topically. Caffeine's evidence base is the strongest among the listed ingredients, with at least one clinical study demonstrating comparable performance to topical minoxidil at a disclosed concentration.

However, the finished formula has not been evaluated as a proprietary product in any published clinical trial. Ingredient concentrations are not disclosed. Several marketing statistics — including "56% thicker hair in 18 weeks," a "93% success rate," and varying review counts across the same page — lack publicly available methodology or present inconsistencies.

The biotin evidence is notably weaker than the product's positioning suggests. A 2024 systematic review found no difference between biotin and placebo for hair growth in the highest-quality study examined. This is worth factoring into any evaluation of the formula's overall research backing.

The product page describes a 30-day money-back guarantee, though the Terms of Service disclose a potential 15% restocking fee. Orders ship from a New Jersey warehouse, and customer support is available by email and phone.

Consumers who have completed their own research and want to review the full product details can do so. Complete product details, current pricing, and published terms are available by viewing the current Akemi Hair Glow offer (official Akemi Hair Glow page).

Contact Information

Per the company's published contact information:

Company: Akemi Hair Glow

Email: [email protected]

Phone: +1 (866) 697-4823

Shipping Origin: New Jersey, United States (per the company's FAQ)

Website: buyskyline.co

Disclaimers

Content and Consumer Information Disclaimer: This article is an informational overview and does not constitute medical, health, or dermatological advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented on the publicly available product website and related materials. Readers are encouraged to verify all claims directly on the official website and to consult a qualified healthcare professional before beginning any topical hair treatment.

Health and Hair Loss Notice: Hair loss can result from numerous causes, including genetics, hormonal changes, nutritional deficiencies, medical conditions, medications, and stress. Topical cosmetic products are not substitutes for professional dermatological evaluation and treatment. If you are experiencing sudden, severe, or patchy hair loss, consult a healthcare provider. Individual results vary based on factors including the type and cause of hair loss, genetic factors, hormonal profiles, consistency of use, and other individual variables. While some consumers report improvements, results are not guaranteed.

Results May Vary: Individual results will vary based on numerous factors, including age, baseline hair condition, the type and underlying cause of hair loss, hormonal factors, consistency of use, genetic factors, current medications, and other individual variables. While some customers report improvements, results are not guaranteed. People who write reviews are self-selected — satisfied customers are more likely to post feedback than those with neutral or negative experiences.

FTC Affiliate Disclosure: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on published research and publicly available information from the company's official website.

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were based on information published on the official product website at the time of publication (March 2026) and are subject to change without notice. Always verify current pricing, promotions, and terms on the official website before making a purchase.

Publisher Responsibility: The publisher of this article has made every effort to ensure accuracy at the time of publication. The publisher does not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with the company and their healthcare provider before making decisions.

In the fast-paced and unpredictable ecosystem of cryptocurrency and venture capital, recent social media discussions have highlighted the extraordinary investment foresight demonstrated by Sam Bankman-Fried, the disgraced founder and former CEO of collapsed crypto exchange FTX. This, even as its founder’s legal troubles continue to cast a long shadow.A widely shared update drew attention to an early allocation of $500 million into artificial intelligence leader Anthropic.

The original framing attributed the move directly to Sam Bankman-Fried and estimated its current worth at roughly $70 billion, generating shock and debate across platforms.

Community clarifications quickly adjusted the narrative: the stake actually belonged to FTX itself, representing about an 8 percent ownership slice.

The position was fully liquidated during 2024 bankruptcy proceedings for $1.3 billion.

maturing is realizing that FTX was one of the best investors in crypto industry:

> $500M in Anthropic would now be worth roughly $30.4B
> $1B in Solana would now be worth roughly $5.1B
> $648M in Robinhood would be $5.7B
> $100M in Sui would be $1.2B
> $1.15B in Genesis… pic.twitter.com/WhxGbWdMGV

— Loshmi (@loshmi) March 17, 2026

At Anthropic’s latest reported valuation near $380 billion, that same portion would theoretically stand at approximately $30 billion today—still representing an enormous return but notably lower than the initial viral claim.

A proxy account associated with Bankman-Fried even highlighted how bankruptcy lawyers once described the holding as “worth nothing” before its sale.

This discussion quickly evolved into a deeper examination of the exchange’s overall track record.

Another high-engagement post argued that FTX stood among the sharpest investors in the entire crypto and technology landscape.

The analysis compiled a range of strategic bets that aligned remarkably with surging market trends.

A $1 billion position in the Solana blockchain ecosystem, for example, would now equate to roughly $5.1 billion.

Holdings in the Robinhood fintech platform, initially valued at $648 million, could reach about $5.7 billion.

Further examples included a $100 million commitment to the Sui network, potentially worth $1.2 billion today; $1.15 billion in Bitcoin mining operation Genesis Digital Assets, now estimated at $3.5 billion; and $700 million routed through K5 Global into SpaceX, translating to around $3 billion in current terms.

Taken together, these positions suggest the exchange’s $4.7 billion investment base might have expanded to $52.5 billion in today’s market—an unrealized uplift of nearly $48 billion.

The portfolio spanned cutting-edge artificial intelligence, layer-1 blockchains, traditional brokerage platforms, crypto infrastructure, and space technology, perfectly positioned for the multi-year bull run that followed the firm’s implosion.

Yet these hypothetical windfalls are inseparable from the scandal that defined FTX’s end.

The capital deployed came from customer deposits rather than proprietary funds, resulting in fraud convictions, the exchange’s dramatic failure, and ongoing restitution efforts.

Bankruptcy administrators sold assets—including the Anthropic stake—well before peak valuations, prioritizing creditor recovery over long-term holding.

Online commentary frequently underscores the irony: had operations remained compliant and sustainable, superior investment choices might have fully repaid victims while still delivering outsized gains.

These conversations serve as a stark reminder of venture capital’s high-stakes nature in emerging fields.

They underscore the thin line between visionary strategy and ethical failure, while reigniting debates around regulation, leadership accountability, and the true cost of financial misconduct in crypto. As artificial intelligence and digital asset valuations climb higher, the FTX story clearly remains a cautionary tale about the difference between spotting winners and safeguarding the capital entrusted to you.

AI is scaling faster, and the ripple effects are hitting crypto in a big way. 

Notably, a standout example comes from World Financial Liberty (WLFI), which recently launched the AgentPay SDK. Designed as a toolkit for AI agents, it enables them to make payments, and transfer money using USD1 across EVM chains. In short, allowing transactions to happen without any human intervention.

However, it is Bittensor [TAO] that is truly stealing the spotlight. At a recent event, NVIDIA CEO Jensen Huang discussed Bittensor’s latest AI model: A huge 72-billion-parameter model trained by 70+ contributors over regular internet. In fact, it’s the largest model ever trained on fully decentralized infrastructure. 

Source: TradingView (TAO/USDT) Given this, TAO’s 24% rally so far this year makes a lot of sense.

For context, Bittensor builds a decentralized network for AI models, and its recent achievement is grabbing attention, especially from top tech players. And the timing couldn’t be better: The AI agent market is booming. In just 90 days, teams deployed 14,500 AI agents across crypto, running arbitrage, LP rebalancing, and yield optimization nonstop.

Taken together, it’s clear that Bittensor’s AI-driven network is growing in step with the rising demand for AI agents. The big question now: With analysts eyeing a potential rally to $1,000, is that too optimistic, or is TAO really in position to make it happen?

The AI hype around TAO pushes price to finally catch up Hype only turns into real value when smart money starts paying attention.

So, even though Bittensor’s AI model grabbed headlines and caught the eyes of tech players, that alone doesn’t move TAO’s price. For the network to really grow, serious capital needs to flow in, incentivizing developers and supporting meaningful activity. Notably, that’s where the actual data becomes important.

Take a closer look: The Grayscale TAO Trust was trading at a 50% premium to NAV, 75% of TAO’s supply is staked, at press time, and the network generated $43 million in Q1 revenue from real AI customers. These numbers show that behind the hype, there’s genuine adoption driving TAO’s momentum, giving the network a stronger foundation for the AI-crypto wave.

Source: CryptoQuant On top of that, a recent CryptoQuant report shows TAO’s 90-day Spot Taker CVD pointing to steady buyer pressure since the $154 bottom, highlighting consistent demand from the market.

When you put it all together, strong institutional capital, high staking levels, real revenue from AI customers, and solid on-chain metrics, it’s clear that smart money is starting to catch up to the AI hype around Bittensor. 

From a technical perspective, that’s why a $1,000 target for TAO isn’t just speculation or a shot in the dark. Instead, real-world adoption, institutional confidence, and growing network activity support it, showing that Bittensor’s AI-driven infrastructure can lead the next wave of the AI-crypto momentum.

Final Summary 14,500 AI agents deployed in 90 days, a 72B-parameter decentralized model, and strong adoption show Bittensor’s network is growing with real demand. High staking, $43 million Q1 revenue, and steady buyer pressure signal smart money is backing TAO, supporting a $1,000 target.

In a key step toward democratizing artificial intelligence, Tether’s QVAC division has introduced the inaugural cross-platform system for fine-tuning Microsoft’s BitNet 1-bit large language models using Low-Rank Adaptation (LoRA) techniques. Integrated into the QVAC Fabric platform and unveiled on March 17, 2026, this update now reportedly slashes the massive memory and processing demands typically associated with advanced AI development.

It opens the door for training and running billion-parameter models directly on ordinary laptops, everyday graphics cards, and even the latest smartphones—no enterprise servers or expensive cloud subscriptions required.

For years, creating and refining sophisticated language models has demanded specialized, high-cost hardware from NVIDIA or vast cloud resources, effectively reserving cutting-edge AI for a handful of well-resourced corporations.

This new framework breaks those restrictions by delivering seamless LoRA adaptation and accelerated inference across diverse consumer-grade processors.

Support spans Intel and AMD GPUs, Apple’s M-series silicon, and mobile graphics units including Adreno, Mali, and Apple Bionic chips found in popular Android and iOS devices.

Real-world testing highlights the breakthrough’s practicality.

Engineers fine-tuned a 125-million-parameter BitNet model on a Samsung Galaxy S25 in approximately ten minutes, processing a biomedical dataset of around 300 documents totaling roughly 18,000 tokens.

Scaling up, a full 1-billion-parameter version completed the same task in 78 minutes on the Samsung device and 105 minutes on an iPhone 16. Pushing boundaries further, the team successfully adapted models reaching 13 billion parameters on the iPhone 16 alone.

Compared with traditional 4-bit quantized models, the BitNet architecture allows training roughly twice as large on edge hardware while maintaining efficiency.

Inference speeds also surge dramatically.

Mobile GPUs deliver performance between two and eleven times faster than CPUs for these 1-bit models, turning pocket-sized devices into viable AI workstations.

Memory efficiency proves equally transformative: the BitNet-1B variant consumes up to 77.8 percent less video memory than comparable 16-bit models like Gemma-3-1B and 65.6 percent less than Qwen3-0.6B during both training and inference.

These gains create ample headroom for complex personalization tasks that once seemed impossible on consumer gear.

Beyond raw performance, the framework achieves another milestone by enabling LoRA fine-tuning of 1-bit models on non-NVIDIA platforms for the first time.

By keeping all processing local, it strengthens data privacy and eliminates reliance on centralized cloud providers.

This architecture also lays groundwork for practical federated learning, where devices collaboratively refine models while safeguarding sensitive user information.

Tether CEO Paolo Ardoino emphasized the broader vision: intelligence will shape society’s trajectory, and AI must remain open and accessible rather than confined to elite organizations with unlimited budgets.

Centralized training risks stifling innovation and creating fragile ecosystems; by contrast, empowering everyday devices promotes decentralization and inclusivity.

Tether plans sustained investment to advance on-device AI, marking the dawn of an era defined by stable, ubiquitous intelligence.

Full documentation, including technical papers, model adapters, benchmarks, and ready-to-use binaries, appears on Hugging Face.

This launch aligns with Tether’s longstanding commitment to fostering transparent, intermediary-free technologies that place control back in users’ hands. As AI evolves from data-center exclusivity to (gradually) pocket-sized empowerment, frameworks like this signal a future where powerful intelligence potentially belongs to everyone.

📊
No votes yet – Be the first to vote

HISTORY crashed the party Tuesday. The new Ethereum History Token launched at $0.50, targeting crypto enthusiasts who can’t get enough of blockchain’s glory days.

The token’s creators want to bottle up Ethereum’s biggest moments into a digital collectible experience. Alex Thompson, the blockchain developer leading the project, thinks there’s real demand for this kind of nostalgic play. His team designed HISTORY to work like a digital archive, capturing everything from early smart contracts to the rise of decentralized apps. And they’re betting people will pay for that trip down memory lane.

Trading volume hit $2 million in the first 24 hours. Not bad for a newcomer.

Community Response Mixed But the reception hasn’t been all roses. Some investors see HISTORY as a clever way to engage with Ethereum’s past, while others question whether nostalgia makes for a solid investment strategy. Cryptocurrency analyst Sarah Lin said the token taps into a niche market, but warned its success depends on keeping people interested long-term.

“Investors might appreciate the novelty, but without continuous innovation, the token risks fading into obscurity,” blockchain analyst John Carter said during a March 24 webinar. He’s probably right about that double-edged sword thing. Nostalgia sells, but it doesn’t always stick around.

The team hosted a virtual conference March 19 to drum up interest. Vitalik Buterin, Ethereum’s co-founder, showed up to talk about preserving blockchain history for future generations. That kind of endorsement doesn’t hurt when you’re trying to build credibility in a crowded market.

HISTORY’s social media numbers tell a different story though. The official Twitter account saw followers jump 35% since launch. People are definitely curious about what Thompson’s team is building, even if they’re not sure it’ll work long-term.

Mobile App Plans The developers announced plans for a mobile app by the end of Q2. The app will feature interactive timelines and quizzes about Ethereum’s development, giving users a more hands-on experience with blockchain history. It’s a smart move if they want to keep people engaged beyond the initial novelty.

They’re also exploring partnerships with educational institutions to get blockchain history into actual curricula. No concrete deals yet, but the idea makes sense. Schools are always looking for ways to teach emerging technologies, and HISTORY could provide a structured approach to understanding how Ethereum evolved. Market participants tracking Nigeria Forces Banks to Deploy AI will find additional context here.

The token’s creators hint at collaborations with blockchain museums for virtual exhibitions too. These would showcase pivotal moments in Ethereum’s timeline, creating an educational platform for both newcomers and crypto veterans. But again, no formal partnerships have been announced. The team seems to have lots of ideas but not many firm commitments.

Regulatory clarity remains a big question mark. Like most new digital assets, HISTORY needs to navigate complex financial regulations. The creators haven’t made detailed disclosures about compliance measures yet, which makes some potential investors nervous. That’s understandable given how quickly regulatory winds can shift in crypto.

Market competition is fierce too. Other niche tokens are fighting for investor attention with their own thematic offerings. HISTORY’s blockchain nostalgia angle is unique, but uniqueness doesn’t guarantee success in a market where attention spans are short and money moves fast.

The project’s roadmap includes plans to expand offerings, but specific details remain under wraps. That lack of transparency could hurt growth if investors don’t get more concrete information soon. People want to know what they’re buying into, especially when the concept is as abstract as “blockchain nostalgia.”

Trading activity has stayed moderate since launch, with investors showing cautious interest. The token’s educational angle appeals to some, but others worry about practical utility beyond collecting digital memories. It’s unclear whether HISTORY can build the kind of sustained user base needed for long-term success.

Thompson’s team has been actively engaging with the community through social media, answering questions and sharing updates about upcoming features. They seem committed to transparency, which is good. But they’ll need to deliver on their promises to keep momentum going.

The token launched during a broader trend toward thematic digital assets. Collectors and investors are exploring new ways to engage with blockchain technology beyond traditional cryptocurrencies. HISTORY fits into that trend, but so do dozens of other projects with their own unique angles. Analysts have drawn connections to Trump Crypto Advisor Gets CLARITY Act amid evolving conditions.

March 22 saw moderate trading volume continue, with no major price swings in either direction. The market seems to be taking a wait-and-see approach, watching to see if HISTORY can deliver on its educational promises. Early adopters are betting the nostalgic angle will pay off, but skeptics worry the concept lacks staying power.

The token’s success will likely depend on execution rather than concept. Plenty of crypto projects have launched with interesting ideas only to fade when they couldn’t deliver real value to users. HISTORY faces the same challenge, just with a blockchain history twist.

The token’s launch coincided with Ethereum’s ninth anniversary celebrations, creating additional buzz around blockchain heritage preservation. Several crypto influencers with combined followings exceeding 500,000 users promoted HISTORY through sponsored content during launch week.

Major cryptocurrency exchanges Binance and Coinbase haven’t yet listed HISTORY, limiting accessibility for mainstream investors. The token currently trades on smaller platforms like Uniswap and PancakeSwap, where transaction fees can eat into profits for casual buyers.

Frequently Asked QuestionsWhat was HISTORY’s initial trading price and volume?HISTORY launched at $0.50 on March 21 and reached $2 million in trading volume within 24 hours.

Who leads the HISTORY token project?Blockchain developer Alex Thompson leads the team behind the Ethereum History Token project.

Post Views: 10